Showing results (191-200 of 201) with videos related to

Sort By:
Pageof 21
ESMO Open|March 12, 2021
Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 studyJ Sastre, P García-Alfonso, J M Viéitez, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 27, 2023
A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patientsM Toledano-Fonseca, M A Gómez-España, E Élez, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointestinal registryT Macarulla, A Muñoz, E Martínez de Castro, et al.
ESMO Open|September 4, 2025
Clinical validation of liquid biopsy-RECIST (LB-RECIST) in metastatic colorectal cancer (mCRC) patients: findings from the PLATFORM-B studyV Martelli, J Vidal, J Gibert, et al.
Scientific Reports|May 18, 2019
Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancerA Borrero-Palacios, A Cebrián, M T Gómez Del Pulgar, et al.
Scientific Reports|February 24, 2019
Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancerA Borrero-Palacios, A Cebrián, M T Gómez Del Pulgar, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Safety and efficacy of encorafenib-cetuximab combination in BRAF V600E -mutated metastatic colorectal cancer: real-world evidence from the CONFIDENCE Spanish multicenter studyA Fernández-Montes, J Ros, P García-Alfonso, et al.
European Journal of Cancer (Oxford, England : 1990)|July 29, 2018
First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD studyE Aranda, P García-Alfonso, M Benavides, et al.
Breast Disease|October 9, 2023
Observational analysis of clinical and pathological characteristics and their prognostic impact in Mexican patients with breast cancer: A multi-center studyAnna Gozalishvilli-Boncheva, Iván R Gonzalez-Espinoza, Abraham Castro-Ponce, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2016
ESMO consensus guidelines for the management of patients with metastatic colorectal cancerE Van Cutsem, A Cervantes, R Adam, et al.
Pageof 21